New targets and therapies for gastrointestinal stromal tumors.

Abstract excerpt

INTRODUCTION: The majority of gastrointestinal stromal tumors (GIST) are driven by an abnormal receptor tyrosine kinase (RTK) signaling, occurring mainly due to somatic mutations in KIT or platelet derived growth factor receptor alpha (PDGFRA). Although the introduction of tyrosine kinase inhibitors (TKIs) has revolutionized therapy for GIST patients, with time the vast majority of them develop TKI resistance....

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Drug Design
• Drug Resistance, Neoplasm
• Gastrointestinal Neoplasms
• Gastrointestinal Stromal Tumors